newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - MEREO BIOPHARMA GROUP PLC

  • Explicit Guidance:

    • Profitability: Projected to achieve full-year profitability in 2027 with an intention to sustain it.
    • R&D Spend: Capped under $350 million for the upcoming year.
    • SG&A Spend: Capped under $375 million for the upcoming year.
    • Base Business Growth: Historical growth rate of >20% annually (noted 20% last year, the slowest in recent history).
    • Revenue Forecast: No specific quantitative forecasts provided for the two new gene therapy launches (Fiuvi and Genglycos) until 6 quarters of experience are available.
    • Balance Sheet: Sold two product rights (PRVs) adding $350 million, resulting in a cash position exceeding $700 million.
  • Business-Segment Outlook:

    • Commercial Base (4 Programs): Expected to continue growing >20% driven by population expansion, new territory launches (e.g., Japan, Middle East), and the launch of Dojolvi.
    • Gene Therapy Launches:
      • Fiuvi (Sanfilippo Type A): Launching with high urgency; estimated 3,000–5,000 commercially accessible patients globally; approx. 300–400 potentially treatable US patients.
      • Genglycos (GSD1A): Launching with high urgency; estimated 1,600–2,000 patients; expected to take longer to ramp than Fiuvi.
    • New Launch Metrics: Specific data on start forms, scheduled infusions, reimbursed patients, and revenue for new launches to be disclosed in January.
    • Pipeline (Osteogenesis Imperfecta - CitrusMap): Pursuing further development based on robust data showing ~30% increase in bone mineral density (BMD) and significant improvements in vertebral column fractures (94% reduction). Will continue to fight for approval despite missing primary fracture endpoints in the initial study.
    • Pipeline (OTC - 301): Phase 3 data shows excellent ammonia control and improved Global Impression Scores (89%+ of patients rated "much better" or "very much better"). Open-label extension aims to determine if patients can discontinue diet and standard-of-care drugs.
    • Program Exclusions: The Angelman Syndrome program has been set aside.
  • Market and Competitive Outlook:

    • Competitive Landscape (CitrusMap): Demonstrated superiority over current standard of care (bisphosphonates) in head-to-head testing for BMD; expected to be the only option in the rare disease space.
    • Pricing and Market Access: No specific pricing updates; reliance on established commercial infrastructure to support new launches.
    • Market Perception: Management notes a "turning corner" from recent clinical misses, shifting focus to high-value programs with clear commercial potential.
  • Macro / Industry Outlook:

    • Regulatory Environment (FDA): Management expresses confidence in the current FDA team (CBER/CEDAR), noting a shift toward "professional, rational thinking" and a "rare disease framework" supportive of novel endpoints. Anticipates ongoing discussions rather than an immediate "yes/no" decision on CitrusMap.
    • Regulatory Strategy: Willing to pursue alternative trial designs (e.g., active-comparator, prospective data) rather than a full placebo-controlled trial for CitrusMap to avoid withholding treatment from severe patients.
    • Market Dynamics: Emphasis on "ultra-rare" diseases where loss of exclusivity (LOE) is less impactful due to specialty pharmacy distribution and lack of generic competition.
  • Strategic Initiatives:

    • Cost Reduction: Implemented ~20% staff reduction and 50% R&D spend reduction to drive path to profitability.
    • Capacity Expansion: AAV manufacturing plant in Massachusetts is fully inspected/approved; a second suite is ready for immediate outfitting to increase capacity without building a new facility.
    • Partnerships: Collaborating with Kiron on next-generation versions of Crys-Vita (LOE protection strategy); non-compete agreement in place.
    • LOE Management (Crys-Vita): Patent expiration expected around 2032. Strategy involves developing a next-generation product with improved potency or dosing interval rather than a simple generic.
    • R&D Focus: Narrowing pipeline footprint to high-value programs (CitrusMap, 301 OTC, FX143, 016).
  • Risks and Headwinds to Outlook:

    • Regulatory Uncertainty: CitrusMap approval contingent on FDA acceptance of BMD as a surrogate endpoint or requirement for a new prospective trial (costs and timelines for a new trial are already budgeted for but remain a risk).
    • Clinical Enrollment Challenges: Previous study enrollment difficulties (patients not enrolled due to physician reluctance to withdraw standard care) could impact future trial speed or patient selection.
    • Patient Adoption: Potential hesitation from OTC patients to discontinue existing diet/drug regimens ("security blanket") despite improved outcomes.
    • Commercial Execution: New product revenue contributions are critical for 2027 profitability, though specific guidance is withheld until 6 quarters of data.
    • Clinical Misses: Continued risk of trial failures in the pipeline (acknowledged recent misses in OI and Angelman programs).
  • Management Tone on the Future:

    • Confidence: "Confident in the future" and "encouraged by where we're at."
    • Narrative: Shifting from "turning the corner" after recent setbacks to "sustainable profitability" and "meaningful R&D value."
    • Balance: Acknowledges the difficulty of the past two years ("two big catalysts") but frames the current position as "strong" with a "full balance sheet."
    • Transparency: Willing to discuss regulatory hurdles openly but avoids providing specific dates for FDA decisions.
  • Miscellaneous:

    • Manufacturing Strategy: Preference for in-house AAV manufacturing to manage high costs and complexity rather than relying solely on partners.
    • Patient Education: Emphasis on patient awareness that chronic illness patients may not know what "feeling good" looks like until they experience treatment benefits (specifically noted for OTC program).
    • Timeline for Updates: Full year revenue/launch metrics for new products expected January at competitor conference; no specific forecast for new products until 6 quarters of data.
Company
MEREO BIOPHARMA GROUP PLC
Keywords
MEREO BIOPHARMA GROUP PLC